Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G. Gibney

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association With Outcomes

Clinical Cancer Research

Cancer Research

Oncology

2015

English

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

English

Related publications

Real-World Efficacy and Safety of Nivolumab in Previously-Treated Metastatic Renal Cell Carcinoma, and Association Between Immune-Related Adverse Events and Survival: The Italian Expanded Access Program

Journal for ImmunoTherapy of Cancer

English

Neurological Immune Related Adverse Events Associated With Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook

Journal of Clinical Medicine

2019

English

Association Between Myocarditis and Other Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Use: Analysis of the FDA Adverse Events Reporting System (FAERS)

Journal of Cardiac Failure

Cardiovascular Medicine

Cardiology

2019

English

Pcn111 - Cost Estimate of Immune-Related Adverse Reactions Associated With Innovative Treatments of Metastatic Melanoma

English

EL25Management of Immune-Related Adverse Events

English

MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Journal of Thoracic Oncology

English

Correction To: Serious Adverse Events and Fatal Adverse Events Associated With Nivolumab Treatment in Cancer Patients

Journal for ImmunoTherapy of Cancer

English

819 Extragenital Lichen Sclerosus Is an Immune-Related Adverse Event With Nivolumab

Journal of Investigative Dermatology

English

Cardiovascular Immune‐related Adverse Events: Evaluation, Diagnosis and Management

Asia-Pacific Journal of Clinical Oncology

Medicine

Oncology

2020

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by G. Gibney

Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association With Outcomes

5O_PRA Phase 1b/2 Study of Omaveloxolone in Combination With Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma

Related publications

Real-World Efficacy and Safety of Nivolumab in Previously-Treated Metastatic Renal Cell Carcinoma, and Association Between Immune-Related Adverse Events and Survival: The Italian Expanded Access Program

Neurological Immune Related Adverse Events Associated With Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook

Association Between Myocarditis and Other Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Use: Analysis of the FDA Adverse Events Reporting System (FAERS)

Pcn111 - Cost Estimate of Immune-Related Adverse Reactions Associated With Innovative Treatments of Metastatic Melanoma

EL25Management of Immune-Related Adverse Events

MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Nivolumab

Correction To: Serious Adverse Events and Fatal Adverse Events Associated With Nivolumab Treatment in Cancer Patients

819 Extragenital Lichen Sclerosus Is an Immune-Related Adverse Event With Nivolumab

Cardiovascular Immune‐related Adverse Events: Evaluation, Diagnosis and Management